Volume 68, Issue 4, Pages (October 2015)

Slides:

Advertisements

Similar presentations

Volume 60, Issue 4, Pages (October 2011)

Advertisements

Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine.

Volume 62, Issue 4, Pages (October 2012)

Volume 45, Issue 5, Pages (May 2004)

Judith Bosschieter, André N. Vis, Henk G. van der Poel, Luc M

The PSA Era is not Over for Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

Volume 58, Issue 2, Pages (August 2010)

European Urology Focus

Volume 58, Issue 4, Pages (October 2010)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of Prostate Cancer Marisa Warmuth,

Volume 60, Issue 2, Pages (August 2011)

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Volume 74, Issue 1, Pages (July 2018)

Volume 49, Issue 2, Pages (February 2006)

Volume 51, Issue 1, Pages (January 2007)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

European Urology Oncology

Volume 65, Issue 5, Pages (May 2014)

Volume 68, Issue 1, Pages (July 2015)

Volume 51, Issue 5, Pages (May 2007)

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Volume 50, Issue 5, Pages (November 2006)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 54, Issue 4, Pages (October 2008)

Volume 52, Issue 5, Pages (November 2007)

Volume 68, Issue 1, Pages 5-7 (July 2015)

Volume 71, Issue 3, Pages (March 2017)

Volume 70, Issue 3, Pages (September 2016)

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 69, Issue 4, Pages (April 2016)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 65, Issue 6, Pages (June 2014)

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 64, Issue 4, Pages (October 2013)

Volume 74, Issue 3, Pages (September 2018)

Volume 53, Issue 6, Pages (June 2008)

Volume 70, Issue 2, Pages (August 2016)

Volume 63, Issue 3, Pages (March 2013)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 73, Issue 4, Pages e116-e118 (April 2018)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Sergio Bracarda European Urology Supplements

European Urology is “Your” Journal

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Renal Pyelocalyceal Squamous Cell Carcinoma

Volume 53, Issue 6, Pages (June 2008)

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Annika Berntsen, Poul F. Geertsen, Inge Marie Svane European Urology

Joaquim Bellmunt European Urology Supplements

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Volume 76, Issue 1, Pages (July 2019)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Jan Roigas European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Presentation transcript:

Volume 68, Issue 4, Pages 621-629 (October 2015) CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma Meta H.M. Diekstra, Jesse J. Swen, Epie Boven, Daniel Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Cristina Rodríguez-Antona, Jesus García-Donas, Brian I. Rini, Henk-Jan Guchelaar European Urology Volume 68, Issue 4, Pages 621-629 (October 2015) DOI: 10.1016/j.eururo.2015.04.018 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Patient flowchart on included patients. Fifty-nine patients had to be excluded from association analyses because of non–clear cell subtypes (n=38), relocation to another medical centre during follow-up (n=10), individual genotyping call rates <80% (n=9), double patient (n=1), or a change to another treatment than sunitinib directly after enrolment (n=1). A total of 333 sunitinib-treated metastatic renal cell carcinoma patients were available for analysis of toxicity and survival in the present study. CCF=Cleveland Clinic Foundation; SOGUG=Spanish Oncology Genitourinary Group; SUTOX=Dutch SUTOX consortium. European Urology 2015 68, 621-629DOI: (10.1016/j.eururo.2015.04.018) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Multivariate Cox regression analysis for association of genetic polymorphisms in the ABCB1 haplotype (rs1128503, rs2032582, and rs1045642) with progression-free survival in months, corrected for Heng risk group and study centre. PD=progressive disease. European Urology 2015 68, 621-629DOI: (10.1016/j.eururo.2015.04.018) Copyright © 2015 European Association of Urology Terms and Conditions